SCHEMBL1005097

SCHEMBL1005097

COC(=O)c1cc2c([nH]1)C(=O)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.49
GAA P10253 3/20 0.40
GLA P06280 2/20 0.40
KDM4E B2RXH2 2/20 0.40
XDH P47989 2/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.36
CRBN Q96SW2 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
TSHR P16473 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NGFR P08138 1/20 0.35
ULK1 O75385 1/20 0.35
BAZ2B Q9UIF8 1/20 0.34
BAZ2A Q9UIF9 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SRD5A1 P18405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1004702 0.83 HRH3 (0.45) GAAGLAKDM4EMAPK1MAPT
SCHEMBL1006834 0.80 ALOX15 (0.48) CYP1A2GAAGLAKDM4EMAPK1
SCHEMBL24744334 0.78 ALDH1A1 (0.51) CYP1A2GAAGLAKDM4EXDH
SCHEMBL1056685 0.76 CYP1A2 (0.39) CYP1A2GAAGLAKDM4EXDH
SCHEMBL1056687 0.76 CYP1A2 (0.39) CYP1A2GAAGLAKDM4EXDH
SCHEMBL18250045 0.74 KDM4E (0.51) CYP1A2GAAGLAKDM4EMAPK1
SCHEMBL1160043 0.74 KDM4E (0.48) CYP1A2GAAGLAKDM4EMAPK1
SCHEMBL1005746 0.74 MIF (0.45) CYP1A2GAAXDHMAPTL3MBTL1
SCHEMBL3607213 0.74 CCNC (0.53) CYP1A2GAAGLAKDM4ECCNC
SCHEMBL1005747 0.74 MIF (0.45) CYP1A2GAAXDHMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626860-A1 FUSED PYRROLYL-SULFONAMIDE COMPOUNDS ReWind Therapeutics NV (BE) 2025-10-08 EP disclosed
WO-2024115733-A1 FUSED PYRROLYL-SULFONAMIDE COMPOUNDS REWIND THERAPEUTICS NV (BE) 2024-06-06 WO disclosed
US-7902252-B2 Inhibitors of D-amino acid oxidase SEPRACOR, INC. (US) 2011-03-08 US disclosed
US-7902252-B2 Inhibitors of D-amino acid oxidase SEPRACOR, INC. (US) 2011-03-08 US disclosed
US-7902252-B2 Inhibitors of D-amino acid oxidase SEPRACOR, INC. (US) 2011-03-08 US disclosed
WO-2011011330-A2 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-01-27 WO disclosed
WO-2011011330-A2 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-01-27 WO disclosed
US-20100029737-A1 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2010-02-04 US disclosed
US-20100029737-A1 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2010-02-04 US disclosed
US-20100029737-A1 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2010-02-04 US disclosed
US-20090099248-A1 INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099248-A1 INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, ACHE CYP1A2 2041/4885GAA 309/4885GLA 748/4885
US-20100029737-A1 INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, ACHE CYP1A2 2041/4885GAA 309/4885GLA 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.